1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2030	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	Western	_	_	NNP	_	_	_	_	_
6	Europe	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ten	_	_	CD	_	_	_	_	_
11	most	_	_	RBS	_	_	_	_	_
12	populous	_	_	JJ	_	_	_	_	_
13	nations	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	world	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	estimated	_	_	VBN	_	_	_	_	_
20	number	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	individuals	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	Parkinson	_	_	NNP	_	_	_	_	_
25	’s	_	_	POS	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	PD	_	_	NNP	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	will	_	_	MD	_	_	_	_	_
31	be	_	_	VB	_	_	_	_	_
32	over	_	_	IN	_	_	_	_	_
33	8	_	_	CD	_	_	_	_	_
34	million	_	_	CD	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	main	_	_	JJ	_	_	_	_	_
5	challenges	_	_	NNS	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	faced	_	_	VBN	_	_	_	_	_
9	will	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	development	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	technological	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	cost-effective	_	_	JJ	_	_	_	_	_
17	solutions	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	improve	_	_	VB	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	healthcare	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	these	_	_	DT	_	_	_	_	_
24	patients	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Remote	_	_	JJ	_	_	_	_	_
2	medical	_	_	JJ	_	_	_	_	_
3	communications	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	example	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	form	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	telemedicine	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	decentralized	_	_	VBN	_	_	_	_	_
14	care	_	_	NN	_	_	_	_	_
15	pathways	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	will	_	_	MD	_	_	_	_	_
18	inevitably	_	_	RB	_	_	_	_	_
19	become	_	_	VB	_	_	_	_	_
20	part	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	clinical	_	_	JJ	_	_	_	_	_
24	management	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	such	_	_	JJ	_	_	_	_	_
27	disease	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	tougher	_	_	JJR	_	_	_	_	_
4	hurdles	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	overcome	_	_	VB	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	there	_	_	EX	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	accurate	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	low-cost	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	objective	_	_	JJ	_	_	_	_	_
16	quantification	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	typical	_	_	JJ	_	_	_	_	_
20	motor	_	_	NN	_	_	_	_	_
21	symptoms	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	key	_	_	JJ	_	_	_	_	_
27	issue	_	_	NN	_	_	_	_	_
28	for	_	_	IN	_	_	_	_	_
29	obtaining	_	_	VBG	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	complete	_	_	JJ	_	_	_	_	_
32	indication	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	patient	_	_	NN	_	_	_	_	_
36	’s	_	_	POS	_	_	_	_	_
37	state	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	impairment	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	1967	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	motor	_	_	NN	_	_	_	_	_
7	effects	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	Levodopa	_	_	NNP	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	LD	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	bradykinesia	_	_	NN	_	_	_	_	_
15	have	_	_	VBP	_	_	_	_	_
16	been	_	_	VBN	_	_	_	_	_
17	shown	_	_	VBN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	first	_	_	JJ	_	_	_	_	_
21	time	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	video	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	way	_	_	NN	_	_	_	_	_
28	has	_	_	VBZ	_	_	_	_	_
29	been	_	_	VBN	_	_	_	_	_
30	traced	_	_	VBN	_	_	_	_	_
31	towards	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	quantification	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	movement	_	_	NN	_	_	_	_	_
36	disorders	_	_	NNS	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	their	_	_	PRP$	_	_	_	_	_
39	therapeutic	_	_	JJ	_	_	_	_	_
40	response	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	pathway	_	_	NN	_	_	_	_	_
3	passes	_	_	VBZ	_	_	_	_	_
4	through	_	_	IN	_	_	_	_	_
5	semi-quantitative	_	_	JJ	_	_	_	_	_
6	rating	_	_	NN	_	_	_	_	_
7	scales	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	Hoehn	_	_	NNP	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	Yahr	_	_	NNP	_	_	_	_	_
15	stage	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	unified	_	_	JJ	_	_	_	_	_
18	Parkinson	_	_	NNP	_	_	_	_	_
19	’s	_	_	POS	_	_	_	_	_
20	disease	_	_	NN	_	_	_	_	_
21	rating	_	_	NN	_	_	_	_	_
22	scale	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	UPDRS	_	_	NNP	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	which	_	_	WDT	_	_	_	_	_
28	is	_	_	VBZ	_	_	_	_	_
29	still	_	_	RB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	gold	_	_	JJ	_	_	_	_	_
32	standard	_	_	NN	_	_	_	_	_
33	scale	_	_	NN	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	assessing	_	_	VBG	_	_	_	_	_
36	symptoms	_	_	NNS	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	PD	_	_	NNP	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Evaluation	_	_	NN	_	_	_	_	_
2	through	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	UPDRS	_	_	NNP	_	_	_	_	_
5	score	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	subjective	_	_	JJ	_	_	_	_	_
9	process	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	comes	_	_	VBZ	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	global	_	_	JJ	_	_	_	_	_
15	clinical	_	_	JJ	_	_	_	_	_
16	judgment	_	_	NN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	diagnosis	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	which	_	_	WDT	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	experience	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	specialist	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	movement	_	_	NN	_	_	_	_	_
29	disorders	_	_	NNS	_	_	_	_	_
30	is	_	_	VBZ	_	_	_	_	_
31	crucial	_	_	JJ	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	process	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	fact	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	characterized	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	intrinsic	_	_	JJ	_	_	_	_	_
12	inter-rater	_	_	NN	_	_	_	_	_
13	variability	_	_	NN	_	_	_	_	_
14	due	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	experience	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	examiners	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	influencing	_	_	VBG	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	final	_	_	JJ	_	_	_	_	_
26	judgment	_	_	NN	_	_	_	_	_
27	on	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	impairment	_	_	NN	_	_	_	_	_
30	severity	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	percentage	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	incorrect	_	_	JJ	_	_	_	_	_
5	diagnosis	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	25	_	_	CD	_	_	_	_	_
8	%	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	reported	_	_	VBN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	especially	_	_	RB	_	_	_	_	_
15	when	_	_	WRB	_	_	_	_	_
16	symptoms	_	_	NNS	_	_	_	_	_
17	such	_	_	JJ	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	essential	_	_	JJ	_	_	_	_	_
20	tremor	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	vascular	_	_	JJ	_	_	_	_	_
23	parkinsonism	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	atypical	_	_	JJ	_	_	_	_	_
26	parkinsonian	_	_	NN	_	_	_	_	_
27	syndromes	_	_	NNS	_	_	_	_	_
28	manifest	_	_	VBP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	difficulty	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	overcome	_	_	VB	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	shared	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	all	_	_	DT	_	_	_	_	_
9	clinical	_	_	JJ	_	_	_	_	_
10	assessment	_	_	NN	_	_	_	_	_
11	scales	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	mandatory	_	_	JJ	_	_	_	_	_
16	presence	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	specialist	_	_	NN	_	_	_	_	_
20	:	_	_	:	_	_	_	_	_
21	this	_	_	DT	_	_	_	_	_
22	strongly	_	_	RB	_	_	_	_	_
23	influences	_	_	VBZ	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	clinical	_	_	JJ	_	_	_	_	_
26	management	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	patient	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	as	_	_	IN	_	_	_	_	_
32	all	_	_	PDT	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	therapeutic	_	_	JJ	_	_	_	_	_
35	decisions	_	_	NNS	_	_	_	_	_
36	are	_	_	VBP	_	_	_	_	_
37	restricted	_	_	VBN	_	_	_	_	_
38	at	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	time	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	single	_	_	JJ	_	_	_	_	_
44	medical	_	_	JJ	_	_	_	_	_
45	examination	_	_	NN	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	during	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	time	_	_	NN	_	_	_	_	_
6	interval	_	_	NN	_	_	_	_	_
7	between	_	_	IN	_	_	_	_	_
8	two	_	_	CD	_	_	_	_	_
9	consecutive	_	_	JJ	_	_	_	_	_
10	examinations	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	patient	_	_	NN	_	_	_	_	_
14	’s	_	_	POS	_	_	_	_	_
15	motor	_	_	NN	_	_	_	_	_
16	status	_	_	NN	_	_	_	_	_
17	may	_	_	MD	_	_	_	_	_
18	change	_	_	VB	_	_	_	_	_
19	significantly	_	_	RB	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	out	_	_	IN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	examiner	_	_	NN	_	_	_	_	_
25	’s	_	_	POS	_	_	_	_	_
26	sight	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	chance	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	monitoring	_	_	VBG	_	_	_	_	_
5	any	_	_	DT	_	_	_	_	_
6	change	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	impairment	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	PD	_	_	NN	_	_	_	_	_
12	subjects	_	_	NNS	_	_	_	_	_
13	over	_	_	IN	_	_	_	_	_
14	time	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	possibly	_	_	RB	_	_	_	_	_
17	daily	_	_	RB	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	domestic	_	_	JJ	_	_	_	_	_
22	environment	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	could	_	_	MD	_	_	_	_	_
25	have	_	_	VB	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	strong	_	_	JJ	_	_	_	_	_
28	impact	_	_	NN	_	_	_	_	_
29	on	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	clinical	_	_	JJ	_	_	_	_	_
32	management	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	patients	_	_	NNS	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	consequently	_	_	RB	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	on	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	long-term	_	_	JJ	_	_	_	_	_
43	costs	_	_	NNS	_	_	_	_	_
44	for	_	_	IN	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	healthcare	_	_	NN	_	_	_	_	_
47	system	_	_	NN	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	attempt	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	address	_	_	VB	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	challenges	_	_	NNS	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	quantify	_	_	VB	_	_	_	_	_
10	motor	_	_	NN	_	_	_	_	_
11	symptoms	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	motion	_	_	NN	_	_	_	_	_
14	analysis	_	_	NN	_	_	_	_	_
15	studies	_	_	NNS	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	played	_	_	VBN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	growing	_	_	VBG	_	_	_	_	_
20	role	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	managing	_	_	VBG	_	_	_	_	_
23	subjects	_	_	NNS	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	PD	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	exploring	_	_	VBG	_	_	_	_	_
28	kinematic	_	_	JJ	_	_	_	_	_
29	variables	_	_	NNS	_	_	_	_	_
30	on	_	_	IN	_	_	_	_	_
31	gait	_	_	NN	_	_	_	_	_
32	;	_	_	:	_	_	_	_	_
33	tremor	_	_	NN	_	_	_	_	_
34	;	_	_	:	_	_	_	_	_
35	bradykinesia	_	_	NN	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	rigidity	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Motion	_	_	NN	_	_	_	_	_
2	capture	_	_	NN	_	_	_	_	_
3	systems	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	reference	_	_	NN	_	_	_	_	_
7	standard	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	motion	_	_	NN	_	_	_	_	_
10	analysis	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	but	_	_	CC	_	_	_	_	_
13	they	_	_	PRP	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	expensive	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	non-portable	_	_	JJ	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	so	_	_	IN	_	_	_	_	_
20	their	_	_	PRP$	_	_	_	_	_
21	use	_	_	NN	_	_	_	_	_
22	is	_	_	VBZ	_	_	_	_	_
23	limited	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	laboratory	_	_	NN	_	_	_	_	_
26	environments	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	scientific	_	_	JJ	_	_	_	_	_
29	research	_	_	NN	_	_	_	_	_
30	rather	_	_	RB	_	_	_	_	_
31	than	_	_	IN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	a	_	_	DT	_	_	_	_	_
34	routine	_	_	JJ	_	_	_	_	_
35	clinical	_	_	JJ	_	_	_	_	_
36	use	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	order	_	_	NN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	overcome	_	_	VB	_	_	_	_	_
7	these	_	_	DT	_	_	_	_	_
8	hurdles	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	urgent	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	find	_	_	VB	_	_	_	_	_
15	automatic	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	cost-effective	_	_	JJ	_	_	_	_	_
18	solutions	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	capable	_	_	JJ	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	providing	_	_	VBG	_	_	_	_	_
23	accurate	_	_	JJ	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	objective	_	_	JJ	_	_	_	_	_
26	kinematic	_	_	JJ	_	_	_	_	_
27	measures	_	_	NNS	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	motor	_	_	NN	_	_	_	_	_
30	performance	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	automatic	_	_	JJ	_	_	_	_	_
33	scores	_	_	NNS	_	_	_	_	_
34	that	_	_	WDT	_	_	_	_	_
35	are	_	_	VBP	_	_	_	_	_
36	well	_	_	RB	_	_	_	_	_
37	correlated	_	_	VBN	_	_	_	_	_
38	to	_	_	TO	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	standard	_	_	JJ	_	_	_	_	_
41	clinical	_	_	JJ	_	_	_	_	_
42	ones	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	various	_	_	JJ	_	_	_	_	_
4	technological	_	_	JJ	_	_	_	_	_
5	approaches	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	proposed	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	analysis	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	movement	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	PD	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	including	_	_	VBG	_	_	_	_	_
18	wearable	_	_	JJ	_	_	_	_	_
19	sensor	_	_	NN	_	_	_	_	_
20	networks	_	_	NNS	_	_	_	_	_
21	based	_	_	VBN	_	_	_	_	_
22	on	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	use	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	inertial	_	_	JJ	_	_	_	_	_
27	measurement	_	_	NN	_	_	_	_	_
28	units	_	_	NNS	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	IMUs	_	_	NNP	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	smartphones	_	_	NNS	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	active	_	_	JJ	_	_	_	_	_
36	vision	_	_	NN	_	_	_	_	_
37	systems	_	_	NNS	_	_	_	_	_
38	based	_	_	VBN	_	_	_	_	_
39	on	_	_	IN	_	_	_	_	_
40	new	_	_	JJ	_	_	_	_	_
41	low-cost	_	_	JJ	_	_	_	_	_
42	RGB-Depth	_	_	NNP	_	_	_	_	_
43	optical	_	_	JJ	_	_	_	_	_
44	devices	_	_	NNS	_	_	_	_	_
45	such	_	_	JJ	_	_	_	_	_
46	as	_	_	IN	_	_	_	_	_
47	Microsoft	_	_	NNP	_	_	_	_	_
48	Kinect®	_	_	NNP	_	_	_	_	_
49	(	_	_	-LRB-	_	_	_	_	_
50	Microsoft	_	_	NNP	_	_	_	_	_
51	Corporation	_	_	NNP	_	_	_	_	_
52	,	_	_	,	_	_	_	_	_
53	Redmond	_	_	NNP	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	WA	_	_	NNP	_	_	_	_	_
56	,	_	_	,	_	_	_	_	_
57	USA	_	_	NNP	_	_	_	_	_
58	)	_	_	-RRB-	_	_	_	_	_
59	and	_	_	CC	_	_	_	_	_
60	Intel	_	_	NNP	_	_	_	_	_
61	RealSense®	_	_	NNP	_	_	_	_	_
62	SR300	_	_	NNP	_	_	_	_	_
63	(	_	_	-LRB-	_	_	_	_	_
64	Intel	_	_	NNP	_	_	_	_	_
65	Corporation	_	_	NNP	_	_	_	_	_
66	,	_	_	,	_	_	_	_	_
67	Santa	_	_	NNP	_	_	_	_	_
68	Clara	_	_	NNP	_	_	_	_	_
69	,	_	_	,	_	_	_	_	_
70	CA	_	_	NNP	_	_	_	_	_
71	,	_	_	,	_	_	_	_	_
72	USA)[26	_	_	NNP	_	_	_	_	_
73	]	_	_	-RRB-	_	_	_	_	_
74	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	basis	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	considerations	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	we	_	_	PRP	_	_	_	_	_
9	propose	_	_	VBP	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	integration	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	two	_	_	CD	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	sensor-based	_	_	JJ	_	_	_	_	_
16	subsystems	_	_	NNS	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	single	_	_	JJ	_	_	_	_	_
20	solution	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	objective	_	_	JJ	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	accurate	_	_	JJ	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	automated	_	_	JJ	_	_	_	_	_
28	assessment	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	some	_	_	DT	_	_	_	_	_
31	standard	_	_	JJ	_	_	_	_	_
32	tasks	_	_	NNS	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	upper	_	_	JJ	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	lower	_	_	JJR	_	_	_	_	_
38	limbs	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	as	_	_	IN	_	_	_	_	_
41	defined	_	_	VBN	_	_	_	_	_
42	in	_	_	IN	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	motor	_	_	NN	_	_	_	_	_
45	examination	_	_	NN	_	_	_	_	_
46	section	_	_	NN	_	_	_	_	_
47	(	_	_	-LRB-	_	_	_	_	_
48	Section	_	_	NN	_	_	_	_	_
49	3	_	_	CD	_	_	_	_	_
50	)	_	_	-RRB-	_	_	_	_	_
51	of	_	_	IN	_	_	_	_	_
52	UPDRS	_	_	NNP	_	_	_	_	_
53	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	first	_	_	JJ	_	_	_	_	_
3	component	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	active	_	_	JJ	_	_	_	_	_
7	vision	_	_	NN	_	_	_	_	_
8	system	_	_	NN	_	_	_	_	_
9	dedicated	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	analysis	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	motor	_	_	NN	_	_	_	_	_
16	tasks	_	_	NNS	_	_	_	_	_
17	related	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	upper	_	_	JJ	_	_	_	_	_
20	limbs	_	_	NNS	_	_	_	_	_
21	;	_	_	:	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	second	_	_	JJ	_	_	_	_	_
24	applies	_	_	VBZ	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	body	_	_	NN	_	_	_	_	_
27	sensor	_	_	NN	_	_	_	_	_
28	network	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	BSN	_	_	NN	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	approach	_	_	NN	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	wireless	_	_	JJ	_	_	_	_	_
35	wearable	_	_	JJ	_	_	_	_	_
36	sensors	_	_	NNS	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	analysis	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	lower	_	_	JJR	_	_	_	_	_
43	limb	_	_	NN	_	_	_	_	_
44	tasks	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	technical	_	_	JJ	_	_	_	_	_
3	details	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	both	_	_	DT	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	validation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	their	_	_	PRP$	_	_	_	_	_
11	accuracy	_	_	NN	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	UPDRS	_	_	NNP	_	_	_	_	_
14	automatic	_	_	JJ	_	_	_	_	_
15	scoring	_	_	NN	_	_	_	_	_
16	systems	_	_	NNS	_	_	_	_	_
17	have	_	_	VBP	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	already	_	_	RB	_	_	_	_	_
20	presented	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	previous	_	_	JJ	_	_	_	_	_
23	works	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	will	_	_	MD	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	briefly	_	_	RB	_	_	_	_	_
28	summarized	_	_	VBN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	Materials	_	_	NNP	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	Methods	_	_	NNPS	_	_	_	_	_
34	section	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	gesture-based	_	_	JJ	_	_	_	_	_
3	human	_	_	JJ	_	_	_	_	_
4	machine	_	_	NN	_	_	_	_	_
5	interface	_	_	NN	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	developed	_	_	VBN	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	part	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	solution	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	simplify	_	_	VB	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	interaction	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	self-management	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	system	_	_	NN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	people	_	_	NNS	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	impairment	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	view	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	a	_	_	DT	_	_	_	_	_
34	possible	_	_	JJ	_	_	_	_	_
35	use	_	_	NN	_	_	_	_	_
36	at	_	_	IN	_	_	_	_	_
37	home	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	system	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	able	_	_	JJ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	analyze	_	_	VB	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	automatically	_	_	RB	_	_	_	_	_
9	score	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	patient	_	_	NN	_	_	_	_	_
12	movements	_	_	NNS	_	_	_	_	_
13	during	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	performance	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	UPDRS	_	_	NNP	_	_	_	_	_
18	tasks	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	it	_	_	PRP	_	_	_	_	_
5	archives	_	_	VBZ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	Cloud	_	_	NNP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	kinematic	_	_	JJ	_	_	_	_	_
11	data	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	score	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	video	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	each	_	_	DT	_	_	_	_	_
20	motor	_	_	NN	_	_	_	_	_
21	performance	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	guaranteeing	_	_	VBG	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	remote	_	_	JJ	_	_	_	_	_
26	supervision	_	_	NN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	clinicians	_	_	NNS	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	overcoming	_	_	VBG	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	mandatory	_	_	JJ	_	_	_	_	_
33	presence	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	specialist	_	_	NN	_	_	_	_	_
37	during	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	execution	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	motor	_	_	NN	_	_	_	_	_
43	activities	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	view	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	decentralized	_	_	VBN	_	_	_	_	_
8	approach	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	clinical	_	_	JJ	_	_	_	_	_
12	management	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	patient	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	issue	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	acceptability	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	usability	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	integrated	_	_	VBN	_	_	_	_	_
26	system	_	_	NN	_	_	_	_	_
27	has	_	_	VBZ	_	_	_	_	_
28	been	_	_	VBN	_	_	_	_	_
29	evaluated	_	_	VBN	_	_	_	_	_
30	through	_	_	IN	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	standard	_	_	JJ	_	_	_	_	_
33	questionnaire	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	integrated	_	_	JJ	_	_	_	_	_
3	system	_	_	NN	_	_	_	_	_
4	here	_	_	RB	_	_	_	_	_
5	presented	_	_	VBN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	aimed	_	_	VBN	_	_	_	_	_
8	at	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	more	_	_	RBR	_	_	_	_	_
11	comprehensive	_	_	JJ	_	_	_	_	_
12	evaluation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	neuro-motor	_	_	NN	_	_	_	_	_
16	status	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	PD	_	_	NN	_	_	_	_	_
19	subjects	_	_	NNS	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	decentralized	_	_	VBN	_	_	_	_	_
23	approach	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	could	_	_	MD	_	_	_	_	_
27	represent	_	_	VB	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	new	_	_	JJ	_	_	_	_	_
30	example	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	an	_	_	DT	_	_	_	_	_
33	accurate	_	_	JJ	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	feasible	_	_	JJ	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	cost-effective	_	_	JJ	_	_	_	_	_
38	strategy	_	_	NN	_	_	_	_	_
39	for	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	clinical	_	_	JJ	_	_	_	_	_
42	management	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	PD	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_

